Surgery vs Definitive RT for Pharyngeal and Laryngeal SCC

ReachMD Healthcare Image

Locally advanced squamous cell carcinoma (SCC) of the pharynx and larynx has two accepted curative paths: primary surgery followed by adjuvant radiotherapy (RT), or definitive RT, often with concurrent systemic therapy. Although both approaches are established treatment options, direct comparisons remain challenging because patients selected for surgery frequently differ from those receiving definitive RT.

And so Agolli and colleagues asked a focused question: once these baseline differences are balanced, do the two strategies actually differ in survival, disease control, or toxicity?

Evaluating 2 Curative Paths with Propensity Score Matching
The investigators retrospectively reviewed 309 patients treated in Germany between 2016 and 2023. All had cT3/T4 and/or node-positive SCC of the oropharynx, hypopharynx, or larynx. Of these, 132 received surgery plus adjuvant RT, and 177 received definitive RT.

To reduce selection bias, the team used propensity score matching on T stage, N stage, and age, which produced 61 well-balanced pairs. All patients received volumetric modulated arc therapy. The median high-risk dose was 70.2 Gy for definitive RT and 66 Gy postoperatively. Survival outcomes were calculated from the start of radiotherapy. Because previous malignancies remained significantly more common in the definitive RT group than in the adjuvant RT group after matching (23% vs. 3%; p = 0.002), investigators performed additional multivariable Cox regression analyses to account for this imbalance.

Comparable Survival, with Trends Favoring Surgery
Overall survival (OS) was comparable between treatment groups. Median OS was 81 months following surgery and adjuvant RT but was not reached with definitive RT. Five-year OS rates were 63.9% and 60.0%, respectively (hazard ratio [HR]=1.05; p = 0.70).

Although neither approach demonstrated a statistically significant survival advantage, numerical differences favored surgery followed by adjuvant RT for disease control.

Median progression-free survival (PFS) was 81 months with adjuvant RT versus 43.4 months with definitive RT (HR=1.70; p = 0.092). Five-year PFS rates were 58.7% and 48.1%, respectively.

Similarly, median locoregional recurrence-free survival was not reached in the adjuvant RT group compared with 61.5 months in the definitive RT group (HR=2.25; p = 0.085). Locoregional recurrence occurred in 12% of patients receiving adjuvant RT versus 23% receiving definitive RT (p = 0.149). Most recurrences in both groups developed within previously irradiated regions, with central recurrences at the primary site accounting for 43% of recurrences after adjuvant RT and 64% after definitive RT.

Treatment-Related Toxicities
Fatigue, dysphagia, xerostomia, mucositis, and dermatitis occurred at similar rates in both groups. Lymphedema was the exception as it occurred more often after surgery plus adjuvant RT (33% vs. 13%; p = 0.017). Patients receiving definitive RT tended to receive more cisplatin (56% vs. 38%; p = 0.069) and cetuximab (8% vs. 0%; p = 0.057).

Clinical Implications
These results suggest both strategies remain viable. The numerical edge in disease control after surgery may reflect surgical cytoreduction, pathological risk selection, or residual confounding. The cohort was also treated before perioperative PD-1 blockade gained traction through KEYNOTE-689 and NIVOPOSTOP. The data are therefore best read as a real-world benchmark for radiotherapy-based strategies in the pre-immunotherapy era.

Additionally, several limitations warrant consideration. The retrospective, single-center design and relatively small matched population limit causal interpretation. Previous malignancies remained more common in the definitive RT group (23% vs. 3%; p = 0.002), although additional adjusted analyses did not identify significant survival associations. Differences in systemic therapy, incomplete pathological risk information, and relatively short follow-up further complicate interpretation, particularly for five-year survival estimates.

Overall, surgery plus adjuvant RT and definitive RT delivered similar survival in matched patients with locally advanced pharyngeal and laryngeal SCC. The disease-control trends favoring surgery warrant confirmation in prospective comparative trials.

Reference:
Agolli L, Mici E, Langer C, et al. Surgery followed by adjuvant radiotherapy versus definitive radiotherapy for locally advanced squamous cell carcinoma of the pharynx and larynx: a propensity score-matched analysis. Clin Transl Radiat Oncol. 2026;62:101288. doi:10.1016/j.ctro.2026.101288

Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

NEW FEATURES:

Register

We're glad to see you're enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free